Itolizumab - CISMeF

Preferred Label : Itolizumab;

NCIt definition : A humanized IgG1 monoclonal antibody targeting the T-cell differentiation antigen CD6, with immunmodulating activity. Itolizumab binds to CD6, downregulates the activation and differentiation of T cells, prevents CD6-mediated activation pathways and reduces the synthesis of pro-inflammatory cytokines. CD6, a co-stimulatory molecule predominantly expressed on lymphocytes, is involved in the adhesion and maturation of T cells.;

UNII : XQQ2RHV14N;

CAS number : 1116433-11-4;

Details

Origin ID

C95787;

UMLS CUI

C2987424;

Currated CISMeF NLP mapping
- Itolizumab (substance) [SNOMED CT concept]
- itolizumab [MeSH concept]
- itolizumab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Itolizumab (substance) [SNOMED CT concept]
- Product containing itolizumab (medicinal product) [SNOMED CT concept]
- itolizumab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients